Nepafenac (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nepafenac" in English language version.

refsWebsite

Global rank English rank

13web.archive.org

1^st place

8fda.gov

447^th place

338^th place

7uspto.gov

1,459^th place

991^st place

7nih.gov

4^th place

6sec.gov

572^nd place

436^th place

4drugs.com

399^th place

333^rd place

3doi.org

2^nd place

1tga.gov.au

3,984^th place

2,622^nd place

1drugbank.ca

4,294^th place

6,357^th place

1europa.eu

68^th place

117^th place

1medlineplus.gov

1,581^st place

1,299^th place

1semanticscholar.org

11^th place

8^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1novartis.com

low place

1alcon.com

low place

1forbes.com

54^th place

48^th place

1pharmacompass.com

low place

1drugpatentwatch.com

low place

alcon.com (Global: low place; English: low place)

"Alcon Launches ILEVRO™ (nepafenac ophthalmic suspension) 0.3%, a New Non-Steroidal Anti-Inflammatory Drug, for the Treatment of Pain and Inflammation Associated with Cataract Surgery". Alcon. Archived from the original on December 15, 2018. Retrieved October 30, 2017.

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

"Confirmatory Study Nepafenac 0.3%". ClinicalTrials.gov. U.S. National Library of Medicine. 29 November 2012. Retrieved October 31, 2017.

doi.org (Global: 2^nd place; English: 2^nd place)

Zanetti FR, Fulco EA, Chaves FR, da Costa Pinto AP, Arieta CE, Lira RP (July 2012). "Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial". Indian Journal of Ophthalmology. 60 (4): 277–81. doi:10.4103/0301-4738.98705. PMC 3442462. PMID 22824596.
Gaynes BI, Onyekwuluje A (June 2008). "Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension". Clinical Ophthalmology. 2 (2): 355–68. doi:10.2147/opth.s1067. PMC 2693998. PMID 19668727.
Lane SS, Modi SS, Lehmann RP, Holland EJ (January 2007). "Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery". Journal of Cataract and Refractive Surgery. 33 (1): 53–8. doi:10.1016/j.jcrs.2006.08.043. PMID 17189793. S2CID 38881826.

drugbank.ca (Global: 4,294^th place; English: 6,357^th place)

Drugbank: Nepafenac

drugpatentwatch.com (Global: low place; English: low place)

"Nepafenac - Generic Drug Details". DrugPatentWatch. thinkBiotech LLC. Retrieved October 31, 2017.

drugs.com (Global: 399^th place; English: 333^rd place)

"Nepafenac ophthalmic Use During Pregnancy". Drugs.com. 6 June 2019. Retrieved 13 September 2020.
Nepafenac Monograph
"Generic Nevanac Availability". Drugs.com. Retrieved October 31, 2017.
"Generic Ilevro Availability". Drugs.com. Retrieved October 31, 2017.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Nevanac EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 6 July 2020.

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"Nevanac Approval Package" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on March 1, 2017. Retrieved October 31, 2017.
"Nevanac Statistical Review" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on February 18, 2017. Retrieved October 31, 2017.
"Drug Approval Package: Nevanac (Nepafenac) Ophthalmic Suspension NDA #021862". U.S. Food and Drug Administration (FDA). January 6, 2005. Archived from the original on October 29, 2020. Retrieved October 27, 2017.
"Ilevro Approval Package" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 31, 2017.
"203491 Pharmacology Review" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 31, 2017.
"Ilevro Statistical Review" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on February 28, 2017. Retrieved October 31, 2017.
"Drug Approval Package: Nepafenac Ophthalmic Suspension, 0.3% NDA #203491". U.S. Food and Drug Administration (FDA). April 8, 2013. Archived from the original on April 3, 2021. Retrieved October 27, 2017.
"Nevanac Administrative Documents and Correspondence" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 27, 2017.

forbes.com (Global: 54^th place; English: 48^th place)

"Novartis on the Forbes Top Multinational Performers List". Forbes. Retrieved October 31, 2017.

medlineplus.gov (Global: 1,581^st place; English: 1,299^th place)

"Nepafenac Ophthalmic". MedlinePlus. U.S. National Library of Medicine. Retrieved October 31, 2017.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Zanetti FR, Fulco EA, Chaves FR, da Costa Pinto AP, Arieta CE, Lira RP (July 2012). "Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial". Indian Journal of Ophthalmology. 60 (4): 277–81. doi:10.4103/0301-4738.98705. PMC 3442462. PMID 22824596.
Gaynes BI, Onyekwuluje A (June 2008). "Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension". Clinical Ophthalmology. 2 (2): 355–68. doi:10.2147/opth.s1067. PMC 2693998. PMID 19668727.
Lane SS, Modi SS, Lehmann RP, Holland EJ (January 2007). "Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery". Journal of Cataract and Refractive Surgery. 33 (1): 53–8. doi:10.1016/j.jcrs.2006.08.043. PMID 17189793. S2CID 38881826.

ncbi.nlm.nih.gov

Zanetti FR, Fulco EA, Chaves FR, da Costa Pinto AP, Arieta CE, Lira RP (July 2012). "Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial". Indian Journal of Ophthalmology. 60 (4): 277–81. doi:10.4103/0301-4738.98705. PMC 3442462. PMID 22824596.
Gaynes BI, Onyekwuluje A (June 2008). "Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension". Clinical Ophthalmology. 2 (2): 355–68. doi:10.2147/opth.s1067. PMC 2693998. PMID 19668727.

dailymed.nlm.nih.gov

"Nevanac- nepafenac suspension/ drops". DailyMed. 9 September 2019. Retrieved 6 July 2020.
"Ilevro- nepafenac suspension". DailyMed. 9 September 2019. Retrieved 6 July 2020.

novartis.com (Global: low place; English: low place)

"About Us". Novartis. Retrieved October 27, 2017.

pharmacompass.com (Global: low place; English: low place)

"Nepafenac". U.S. Patents. PharmaCompass. Retrieved October 30, 2017.

sec.gov (Global: 572^nd place; English: 436^th place)

"Alcon Annual Report 2010" (PDF). SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
"Alcon Form 15". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
"Form 20-F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
"Form 20-F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
"Form 20F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
"Form 20-F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 31, 2017.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Lane SS, Modi SS, Lehmann RP, Holland EJ (January 2007). "Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery". Journal of Cataract and Refractive Surgery. 33 (1): 53–8. doi:10.1016/j.jcrs.2006.08.043. PMID 17189793. S2CID 38881826.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

uspto.gov (Global: 1,459^th place; English: 991^st place)

patft.uspto.gov

"United States Patent Application: 6403609". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.
"United States Patent: 7947295". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.
"United States Patent: 8071648". United States Patent and Trademark Office. Archived from the original on August 29, 2021. Retrieved October 31, 2017.
"United States Patent: 8921337". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.
"United States Patent: 9662398". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.

appft1.uspto.gov

"United States Patent Application: 0060122277". United States Patent and Trademark Office. Archived from the original on August 29, 2021. Retrieved October 30, 2017.
"United States Patent Application: 0060257487". United States Patent and Trademark Office. Archived from the original on August 29, 2021. Retrieved October 27, 2017.

web.archive.org (Global: 1^st place; English: 1^st place)

"Nevanac Approval Package" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on March 1, 2017. Retrieved October 31, 2017.
"Nevanac Statistical Review" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on February 18, 2017. Retrieved October 31, 2017.
"Drug Approval Package: Nevanac (Nepafenac) Ophthalmic Suspension NDA #021862". U.S. Food and Drug Administration (FDA). January 6, 2005. Archived from the original on October 29, 2020. Retrieved October 27, 2017.
"Ilevro Statistical Review" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on February 28, 2017. Retrieved October 31, 2017.
"Drug Approval Package: Nepafenac Ophthalmic Suspension, 0.3% NDA #203491". U.S. Food and Drug Administration (FDA). April 8, 2013. Archived from the original on April 3, 2021. Retrieved October 27, 2017.
"Alcon Launches ILEVRO™ (nepafenac ophthalmic suspension) 0.3%, a New Non-Steroidal Anti-Inflammatory Drug, for the Treatment of Pain and Inflammation Associated with Cataract Surgery". Alcon. Archived from the original on December 15, 2018. Retrieved October 30, 2017.
"United States Patent Application: 6403609". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.
"United States Patent Application: 0060122277". United States Patent and Trademark Office. Archived from the original on August 29, 2021. Retrieved October 30, 2017.
"United States Patent Application: 0060257487". United States Patent and Trademark Office. Archived from the original on August 29, 2021. Retrieved October 27, 2017.
"United States Patent: 7947295". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.
"United States Patent: 8071648". United States Patent and Trademark Office. Archived from the original on August 29, 2021. Retrieved October 31, 2017.
"United States Patent: 8921337". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.
"United States Patent: 9662398". United States Patent and Trademark Office. Archived from the original on November 7, 2017. Retrieved October 31, 2017.

Nepafenac (English Wikipedia)

alcon.com (Global: low place; English: low place)

clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)

doi.org (Global: 2nd place; English: 2nd place)

drugbank.ca (Global: 4,294th place; English: 6,357th place)

drugpatentwatch.com (Global: low place; English: low place)

drugs.com (Global: 399th place; English: 333rd place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

forbes.com (Global: 54th place; English: 48th place)

medlineplus.gov (Global: 1,581st place; English: 1,299th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

novartis.com (Global: low place; English: low place)

pharmacompass.com (Global: low place; English: low place)

sec.gov (Global: 572nd place; English: 436th place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

uspto.gov (Global: 1,459th place; English: 991st place)

patft.uspto.gov

appft1.uspto.gov

web.archive.org (Global: 1st place; English: 1st place)

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugbank.ca (Global: 4,294^th place; English: 6,357^th place)

drugs.com (Global: 399^th place; English: 333^rd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

forbes.com (Global: 54^th place; English: 48^th place)

medlineplus.gov (Global: 1,581^st place; English: 1,299^th place)

nih.gov (Global: 4^th place; English: 4^th place)

sec.gov (Global: 572^nd place; English: 436^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

uspto.gov (Global: 1,459^th place; English: 991^st place)

web.archive.org (Global: 1^st place; English: 1^st place)